Clinical efficacy of irbesartan combined with Shensong Yangxin capsule on chronic heart failure complicated with sinus bradycardia

Objective To investigate the clinical effect of irbesartan combined with Shensong Yangxin capsule on chronic heart failure(CHF) complicated with sinus bradycardia. Methods A retrospective study was performed on 89 cases of patients with CHF complicated with sinus bradycardia who were admitted from December 2016 to March 2018.Patients were randomly divided into the combined treatment group(n=45) and irbesartan group(n=44). Patients in the irbesartan group were given irbesartan tables, the others in the combined treatment group were given Shensong Yangxin capsule on the basis of treatment in irbesartan group.The heart function and heart rate indexes of the two groups before and after treatment were compared and analyzed. Results After treatment, the effective rate of the combined treatment group(91.1%) was significantly higher than that of the irbesartan group(81.8%), (P 0.05). After treatment, the improvement degree of each index in the combined treatment group was significantly higher than that in the irbesartan group(P 0.05). After treatment, the improvement degree of each index in the combined treatment group was significantly higher than that in the irbesartan group, (P 0.05). After treatment, the improvement degree of left ventricular function parameters in the combined treatment group was significantly higher than that in the irbesartan group, (P 0.05); after treatment, the combined treatment group was significantly higher than the level of irbesartan group(P<0.05). Conclusion The combination of Shensong Yangxin capsule and irbesartan can improve the cardiac function of patients with CHF complicated with sinus bradycardia, protect the cardiac myocytes, improve heart rate, and ensure the therapeutic effect. Key words: Irbesartan; Shensong Yangxin capsule; Chronic heart failure; Sinus bradycardia